Jing Guo1, Jialiang Ren2, Junkang Shen3, Rui Cheng4, Yexin He5. 1. Department of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China; Department of Radiology, Shanxi Provincial People's Hospital, Taiyuan, China. 2. GE Healthcare China, Beijing, China. 3. Department of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. 4. Department of Neurosurgery, Shanxi Provincial People's Hospital, Taiyuan, China. 5. Department of Radiology, Shanxi Provincial People's Hospital, Taiyuan, China.
Abstract
PURPOSE: We aimed to explore whether multiparametric magnetic resonance imaging (MRI)-based radiomics combined with selected blood inflammatory markers could effectively predict the grade and proliferation in glioma patients. METHODS: This retrospective study included 152 patients histopathologically diagnosed with glioma. Stratified sampling was used to divide all patients into a training cohort (n=107) and a validation cohort (n=45) according to a ratio of 7:3, and five-fold repeat cross-validation was adopted in the training cohort. Multiparametric MRI and clinical parameters, including age, the neutrophil-lymphocyte ratio and red cell distribution width, were assessed. During image processing, image registration and gray normalization were conducted. A radiomics analysis was performed by extracting 1584 multiparametric MRI-based features, and the least absolute shrinkage and selection operator (LASSO) was applied to generate a radiomics signature for predicting grade and Ki-67 index in both training and validation cohorts. Statistical analysis included analysis of variance, Pearson correlation, intraclass correlation coefficient, multivariate logistic regression, Hosmer-Lemeshow test, and receiver operating characteristic (ROC) curve. RESULTS: The radiomics signature demonstrated good performance in both the training and validation cohorts, with areas under the ROC curve (AUCs) of 0.92, 0.91, and 0.94 and 0.94, 0.75, and 0.82 for differentiating between low and high grade gliomas, grade III and grade IV gliomas, and low Ki-67 and high Ki-67, respectively, and was better than the clinical model; the AUCs of the combined model were 0.93, 0.91, and 0.95 and 0.94, 0.76, and 0.80, respectively. CONCLUSION: Both the radiomics signature and combined model showed high diagnostic efficacy and outperformed the clinical model. The clinical factors did not provide additional improvement in the prediction of the grade and proliferation index in glioma patients, but the stability was improved.
PURPOSE: We aimed to explore whether multiparametric magnetic resonance imaging (MRI)-based radiomics combined with selected blood inflammatory markers could effectively predict the grade and proliferation in gliomapatients. METHODS: This retrospective study included 152 patients histopathologically diagnosed with glioma. Stratified sampling was used to divide all patients into a training cohort (n=107) and a validation cohort (n=45) according to a ratio of 7:3, and five-fold repeat cross-validation was adopted in the training cohort. Multiparametric MRI and clinical parameters, including age, the neutrophil-lymphocyte ratio and red cell distribution width, were assessed. During image processing, image registration and gray normalization were conducted. A radiomics analysis was performed by extracting 1584 multiparametric MRI-based features, and the least absolute shrinkage and selection operator (LASSO) was applied to generate a radiomics signature for predicting grade and Ki-67 index in both training and validation cohorts. Statistical analysis included analysis of variance, Pearson correlation, intraclass correlation coefficient, multivariate logistic regression, Hosmer-Lemeshow test, and receiver operating characteristic (ROC) curve. RESULTS: The radiomics signature demonstrated good performance in both the training and validation cohorts, with areas under the ROC curve (AUCs) of 0.92, 0.91, and 0.94 and 0.94, 0.75, and 0.82 for differentiating between low and high grade gliomas, grade III and grade IV gliomas, and low Ki-67 and high Ki-67, respectively, and was better than the clinical model; the AUCs of the combined model were 0.93, 0.91, and 0.95 and 0.94, 0.76, and 0.80, respectively. CONCLUSION: Both the radiomics signature and combined model showed high diagnostic efficacy and outperformed the clinical model. The clinical factors did not provide additional improvement in the prediction of the grade and proliferation index in gliomapatients, but the stability was improved.
Authors: Sofie Van Cauter; Jelle Veraart; Jan Sijbers; Ronald R Peeters; Uwe Himmelreich; Frederik De Keyzer; Stefaan W Van Gool; Frank Van Calenbergh; Steven De Vleeschouwer; Wim Van Hecke; Stefan Sunaert Journal: Radiology Date: 2012-03-08 Impact factor: 11.105
Authors: Quinn T Ostrom; Luc Bauchet; Faith G Davis; Isabelle Deltour; James L Fisher; Chelsea Eastman Langer; Melike Pekmezci; Judith A Schwartzbaum; Michelle C Turner; Kyle M Walsh; Margaret R Wrensch; Jill S Barnholtz-Sloan Journal: Neuro Oncol Date: 2014-07 Impact factor: 12.300
Authors: Jia Shen Jiang; Ye Hua; Xue Jun Zhou; Dan Dan Shen; Jin Long Shi; Min Ge; Qi Nan Geng; Zhong Zheng Jia Journal: Acad Radiol Date: 2018-11-08 Impact factor: 3.173
Authors: Marc A Brockmann; Alf Giese; Kathrin Mueller; Finjap Janvier Kaba; Frank Lohr; Christel Weiss; Stefan Gottschalk; Ingo Nolte; Jan Leppert; Jochen Tuettenberg; Christoph Groden Journal: Neuro Oncol Date: 2007-05-15 Impact factor: 12.300
Authors: R M Bambury; M Y Teo; D G Power; A Yusuf; S Murray; J E Battley; C Drake; P O'Dea; N Bermingham; C Keohane; S A Grossman; E J Moylan; S O'Reilly Journal: J Neurooncol Date: 2013-06-19 Impact factor: 4.130